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Abstract: Superﬁ  cial bladder tumors are the most prevalent form of bladder cancers and 
transurethral resection is the primary surgical modality for those tumors. However, nearly 65% 
of patients will have tumor recurrence in ﬁ  ve years while about 15% will have progression 
to muscle invasion. Thus, the primary therapeutic aim is to prevent multiple recurrences 
and progression to a more advanced, invasive disease. We here report an 87-year-old white 
male patient with invasive bladder cancer who received an unconventional oral regimen of 
D-fraction, the bioactive extract of Maitake mushroom (Grifola frondosa), following endoscopic 
transurethral resection of bladder tumor. Despite a high risk for disease recurrence, follow-up 
yet indicated no clinical evidence of progression of residual disease or recurrence of invasive 
cancer. It has been nearly two years but the patient remains remarkably well and appears to be 
in remission. To our knowledge, this is the ﬁ  rst and only case report of possible disease remis-
sion in a bladder cancer patient after the two-year follow-up of D-fraction regimen, so that 
further studies with long terms are required for drawing a relevant conclusion. Nevertheless, it 
is conceivable that D-fraction is a natural agent that may have clinical implications in patients 
with superﬁ  cial bladder tumors.
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Introduction
Bladder cancer is the second most common urologic malignancy in the United States. 
Tumors fall into two categories: papillary lesions that tend to recur and invasive 
cancer. Although transurethral resection (TUR) is often performed as a primary 
therapy for papillary lesions, 50%–75% of patients will yet recur in ﬁ  ve years and 
10%–20% progress to invasive disease.1 For invasive bladder cancer, radical cystec-
tomy is the gold standard procedure.2,3 Several cytotoxic and immune modifying agents 
have been also used intravesically to treat bladder cancer. Intravesical administration 
of Bacillus Calmette-Guérin (BCG), an attenuated strain of Mycobacterium bovis, 
is the most effective immunotherapy for superﬁ  cial bladder cancer and carcinoma 
in situ (CIS)4 among currently available therapeutic options. However, its beneﬁ  ts 
are sometimes outweighed by its severe side effects including cystitis, fever, allergic 
reactions, sepsis, and even death. These drawbacks thus limit its use in clinical practice, 
requesting a safer and more effective treatment modality with few side effects.
As an alternative approach, many natural agents/substances with low or negligible 
side effects have been gaining more attention for possible therapeutic modalities for 
various human malignancies. Although scientiﬁ  c studies have not been performed 
on most of them to demonstrate their biological and medicinal properties, some 
of them have been well characterized. For example, Maitake mushroom (Grifola 
frondosa) has been extensively studied for its potential medicinal properties and its 
immunomodulatory and antitumor activities have been thus far demonstrated in animals 
and humans.5,6 It is the fact that some cancer patients have been or are still taking a 
commercially available extract of this mushroom for therapeutic purpose.International Journal of General Medicine 2009:2 16
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Case report
An 87-year-old retired OB-GYN physician, with a three-
month history of intermittent hematuria, required emergent 
admission for painless gross hematuria in October, 2006 
after failure to control the bleeding in an ofﬁ  ce cystoscopy. 
He had intermittent painless hematuria for six months prior 
to admission but had been lost to follow up. He also had an 
episode of urinary retention following a colon resection in 
2002 but was not currently on alpha blocker therapy. In fact, 
he was on no medications at time of admission. The ofﬁ  ce 
cystoscopy revealed a large tumor on the right ﬂ  oor of his 
bladder, and satellite tumors surrounded this base appeared 
to be papillary tumors.
The patient was admitted and immediately underwent 
TUR of bladder tumor as he continued bleeding after the 
office cystoscopy. TUR showed multiple papillary and 
large ulcer base and the pathology report indicated he had 
invasive, transitional cell carcinoma (grade 3), T2b Nx Mx 
tumor. When he was discharged home three days after TUR, 
he was referred to a tertiary center to receive his follow-up 
care such as adjuvant chemotherapy, radical cystectomy, 
or external pelvic irradiation. He was also warned that he 
was likely have hematuria in the next six months unless he 
had surgery. However, the patient has refused all of these 
conventional treatments and started having an unconventional 
treatment using two supplements instead. One of the two 
supplements he took was a bioactive extract of Maitake 
mushroom, Maitake D-fraction® (Maitake Products, Inc., 
East Rutherford, NJ), following the recommended daily 
dosage, and the other was vitamin C (2,000 mg daily).
The patient has had no recurrent hematuria, pain, or 
urinary symptoms since then. In fact, ofﬁ  ce examination 
showed that his urine was clear with negative urine cytology, 
negative FISH (ﬂ  uorescence in situ hybridization) test, and 
negative NMP-22 (nuclear matrix protein-22) test. It has been 
nearly two years but his condition yet remains exceptionally 
healthy.
Discussion
The natural history of bladder cancer is one of recurrence 
and progression, with recurrence most common in the ﬁ  rst 
12–24 months.7 Our patient was a high risk for disease recur-
rence, having multiple lesions with a large focus that was 
poorly differentiated carcinoma invading the deep muscle 
(ie, T2b Nx Mx). However, the only interventions our 
patient underwent were TUR of bladder tumor and adjuvant 
D-fraction regimen, because he refused radical cystectomy 
and other conventional interventions. Particularly, since 
radical cystectomy is known as the gold standard procedure 
for such invasive cancer,1,2 performing TUR alone is unlikely 
to remove the whole tumor completely. The patient was then 
warned for disease recurrence unless appropriate post-TUR 
care was given to him. Yet, without any follow-up care, 
he had no recurrent hematuria with all negative results of 
cytology, FISH, and NMP-22 tests, which have exceptional 
sensitivity and speciﬁ  city with a negative predictive value 
of 90.4%–98%.8,9 The patient indeed remains in good patho-
physiological condition without any symptoms of his initial 
disease, indicating possible disease remission.
Maitake D-fraction is not just another mushroom extract 
found in the market but has been scientiﬁ  cally investigated for 
its potential medicinal effects/properties for the past 20 years. 
Besides its conﬁ  rmed immunostimulatory activity, D-fraction 
was found to have antitumor activity in tumor-bearing mice, 
reducing cancer proliferation.6 An early nonrandomized 
clinical study on patients with various cancers also showed 
certain improvements in those cancer patients.10 In addition, 
D-fraction was capable of inducing apoptosis (programmed 
cell death) in human prostate cancer cells11 as well as 90% 
growth reduction in human bladder cancer cells.12 Thus, 
these studies support the notion that D-fraction has potent 
anticancer activity on animal and human malignancies.
Above all, the most important issue of D-fraction would 
be its safety. It is supported by the fact that the US Food and 
Drug Administration (FDA) had exempted D-fraction from a 
Phase I toxicology study. The FDA also approved D-fraction 
for an Investigational New Drug (IND) application to conduct 
a Phase II pilot study on patients with advanced prostate and 
breast cancer, further granting its use in human cases.13
This case study describes an invasive bladder cancer 
patient at a high risk for disease recurrence who only followed 
a D-fraction regimen (with vitamin C) refusing other medi-
cal interventions. The two-year follow-up yet indicated no 
clinical evidence of progression of residual disease or 
recurrence with possible disease remission. However, we 
are recommending him to have additional viable options 
such as cystoscopy, computed tomography scan, or another 
TUR for further assessment and conﬁ  rmation of his latest 
disease status. In addition, a correlation between cancer 
suppression and D-fraction needs to be fully established and 
also this is only one case with merely two-year follow-up, 
thereby requiring more case studies with long terms to draw 
any afﬁ  rmative conclusions. Meanwhile, it is yet plausible 
that D-fraction is a natural, safe, and promising agent that 
may have clinical implications in patients with superﬁ  cial 
bladder cancer.International Journal of General Medicine 2009:2 17
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